AbbVie's Exviera and Viekirax Set To Challenge Sovaldi In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA has given a positive recommendation to two HCV drugs from AbbVie, Exviera and Viekirax, which, if priced competitively, will represent a clear challenge to Gilead’s Sovaldi.